Skip to content
NYSE · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Rafael Holdings, Inc. RFL

10 fiscal years on record · USD · FY2025 reported · SEC filings only
$917,000
▲ 44.0% YoY
$-30.5M
$-18.9M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 917,000.00
Revenue, FY2025 · full 10-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.9 · Net income -30.5
-50M-100M
2016201920222025
Compound annual growth
+30.8%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2025 · Operating -3179.8% · Net ·
-5000%-10000%-15000%
201620202025
ROE
FY2025 · ROE -34.6%
-50%-100%
201620202025
Three returns, three denominators.

Each USD of equity lost 35 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -18.9
-10M-20M
201620202025

Total assetsUSD 114.1M
EquityUSD 94.4M
CashUSD 52.8M
Current ratio4.89×

Equity funds 83% of total assets.

The 10-year record

10 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
RFL, 10-year financial record
Metric 2025202420232022202120202019201820172016
Revenue $B0.00.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.1−0.0−0.1−0.0−0.0−0.0−0.00.00.0
EBITDA $B◌◌−0.0−0.1−0.0−0.0−0.0−0.00.00.0
Income tax $B−0.0−0.0−0.0◌0.00.0−0.00.00.00.0
Net income $B−0.0−0.0−0.0−0.1−0.0−0.0−0.0−0.00.00.0
Free cash flow $B−0.0−0.0◌−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−1.04−1.45−0.08−6.31−1.49−0.66−0.35−0.930.010.06
Dividend / sh $◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend——————————
ROE %−34.6−37.7−1.9−111.9−19.3−9.4−4.3−14.60.3◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures · 1 divergence in 38 reconciliationsAUDITED

Reconciled in 9 of the 10 fiscal years we could check. 1 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 20 checks were skipped: the balance sheet is not tagged before 2017. 14 checks were skipped: cost of revenue is not tagged before 2021. Nine checks were skipped: EPS is not tagged before 2016.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures1 divergent
ActivityPharmaceutical Preparations
Listed onNYSE
Incorporated inDelaware
Fiscal year endsJuly 31
SEC categorysmaller reporting company
Data on record since2016

Share this section

Download image